Mechanisms of DNA-Specific Autoimmunity in Systemic Lupus Erythematosus

系统性红斑狼疮 DNA 特异性自身免疫机制

基本信息

  • 批准号:
    10374852
  • 负责人:
  • 金额:
    $ 49.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-06-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT The hallmark of systemic lupus erythematosus (SLE) is the production of antibodies to nuclear antigens such as ribonucleoproteins and DNA, with the resulting immune complexes causing systemic immune activation and tissue inflammation. High-affinity IgG antibodies to double-stranded DNA (dsDNA) are particularly pathogenic and associate with the severity of tissue damage. The mechanisms of tolerance to self-DNA and of its breakdown in SLE are poorly understood. We have studied these mechanisms by focusing on DNASE1L3, a secreted DNase that is mutated in several cases of early-onset familial SLE. We found that DNASE1L3-deficient mice develop a massive anti- dsDNA antibody response, whereas the response to other antigens was absent or delayed. This response and the ensuing immune activation and tissue damage required innate immune signaling through the adaptor protein MyD88. DNASE1L3-deficient mice and human patients showed the accumulation of genomic DNA within circulating apoptotic microparticles, and this DNA was recognized by autoantibodies in a DNASE1L3-sensitive manner. Thus, DNASE1L3 maintains tolerance to self-DNA by digesting potentially antigenic cell-extrinsic DNA in apoptotic microparticles. The proposed work will apply the newly developed conceptual framework and experimental tools to analyze the fundamental mechanisms of anti-DNA immune responses and their relevance to human SLE. In Aim 1, we will use DNASE1L3-deficient mice as a model of primary anti-dsDNA reactivity to characterize the nature and regulation of DNA-reactive B cells. In Aim 2, we will characterize innate immune mechanisms of anti-DNA antibody response, particularly the identity of MyD88-dependent sensing pathways. In Aim 3, we will translate our findings to human SLE patients, studying the antibody response to DNASE1L3-sensitive chromatin on microparticles. Collectively, these studies would provide insights into the origin and mechanisms of the pathogenic anti-DNA responses in SLE, and facilitate targeted approaches towards their therapeutic blockade.
抽象的 系统性红斑狼疮 (SLE) 的标志是产生抗核抗体 核糖核蛋白和 DNA 等抗原,产生的免疫复合物引起全身性感染 免疫激活和组织炎症。双链 DNA 高亲和力 IgG 抗体 (dsDNA) 具有特别致病性,并且与组织损伤的严重程度相关。这 SLE 患者对自身 DNA 的耐受及其分解的机制尚不清楚。我们有 通过关注 DNASE1L3 研究了这些机制,DNASE1L3 是一种在多种细胞中发生突变的分泌性 DNase。 早发家族性 SLE 病例。我们发现DNASE1L3缺陷的小鼠会产生大量的抗- 双链 DNA 抗体反应,而对其他抗原的反应缺失或延迟。这 反应以及随后的免疫激活和组织损伤需要先天免疫信号传导 通过接头蛋白 MyD88。 DNASE1L3 缺陷小鼠和人类患者表现出 循环凋亡微粒内基因组 DNA 的积累,该 DNA 被自身抗体以 DNASE1L3 敏感的方式识别。因此,DNASE1L3 维持 通过消化凋亡微粒中的潜在抗原细胞外源 DNA 来耐受自身 DNA。 拟议的工作将应用新开发的概念框架和实验工具 分析抗 DNA 免疫反应的基本机制及其与人类的相关性 系统性红斑狼疮。在目标 1 中,我们将使用 DNASE1L3 缺陷小鼠作为初级抗 dsDNA 反应性模型 描述 DNA 反应性 B 细胞的性质和调节。在目标 2 中,我们将描述先天的特征 抗 DNA 抗体反应的免疫机制,特别是 MyD88 依赖性的身份 传感通路。在目标 3 中,我们将把我们的发现转化为人类 SLE 患者,研究 对微粒上 DNASE1L3 敏感染色质的抗体反应。总的来说,这些研究 将提供对 SLE 致病性抗 DNA 反应的起源和机制的见解, 并促进有针对性的治疗封锁方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jill P Buyon其他文献

Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade
母体抗 SSA/Ro 自身抗体经滋养层转运至有快速进展性心脏损伤胎儿中的证据:对新生儿 Fc 受体阻断的意义
  • DOI:
    10.1016/s2665-9913(24)00331-x
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    16.400
  • 作者:
    Jill P Buyon;Philip M Carlucci;Bettina F Cuneo;Mala Masson;Peter Izmirly;Nalani Sachan;Justin S Brandt;Shilpi Mehta-Lee;Marc Halushka;Kristen Thomas;Melanie Fox;Colin KL Phoon;Achiau Ludomirsky;Ranjini Srinivasan;Garrett Lam;Benjamin J Wainwright;Nicola Fraser;Robert Clancy
  • 通讯作者:
    Robert Clancy
Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside
新生儿红斑狼疮的心脏表现:管理指南,整合实验台和病床旁的线索
  • DOI:
    10.1038/ncprheum1018
  • 发表时间:
    2009-03-01
  • 期刊:
  • 影响因子:
    32.700
  • 作者:
    Jill P Buyon;Robert M Clancy;Deborah M Friedman
  • 通讯作者:
    Deborah M Friedman
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
索马鲁肽治疗 2 型糖尿病患者的心脏病研究
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Devyn Zaminski;Amit Saxena;P. Izmirly;Jill P Buyon;H. M. Belmont
  • 通讯作者:
    H. M. Belmont

Jill P Buyon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jill P Buyon', 18)}}的其他基金

Stopping Hydroxychloroquine In Elderly Lupus Disease (SHIELD)
停止使用羟氯喹治疗老年狼疮病 (SHIELD)
  • 批准号:
    10594743
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
健康:利用流行病学促进狼疮治疗和健康
  • 批准号:
    10668437
  • 财政年份:
    2022
  • 资助金额:
    $ 49.38万
  • 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT) - Pain Supplement
狼疮组学皮肤肾脏调查小组 (LOCKIT) - 疼痛补充剂
  • 批准号:
    10861419
  • 财政年份:
    2022
  • 资助金额:
    $ 49.38万
  • 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)
狼疮组学皮肤肾研究小组 (LOCKIT)
  • 批准号:
    10452169
  • 财政年份:
    2022
  • 资助金额:
    $ 49.38万
  • 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)
狼疮组学皮肤肾研究小组 (LOCKIT)
  • 批准号:
    10596281
  • 财政年份:
    2022
  • 资助金额:
    $ 49.38万
  • 项目类别:
HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
健康:利用流行病学促进狼疮治疗和健康
  • 批准号:
    10552857
  • 财政年份:
    2022
  • 资助金额:
    $ 49.38万
  • 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
  • 批准号:
    10250529
  • 财政年份:
    2020
  • 资助金额:
    $ 49.38万
  • 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
  • 批准号:
    10440476
  • 财政年份:
    2020
  • 资助金额:
    $ 49.38万
  • 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
  • 批准号:
    10644022
  • 财政年份:
    2020
  • 资助金额:
    $ 49.38万
  • 项目类别:
Translational Center of Molecular Profiling in Preclinical and Established Lupus (COMPEL)
临床前和已确诊狼疮分子分析转化中心 (COMPEL)
  • 批准号:
    9766075
  • 财政年份:
    2017
  • 资助金额:
    $ 49.38万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 49.38万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了